Mass Tort brief
Mass Tort Litigation Brief: Trial Tests and Settlement Deadlines
Courts press toward critical benchmarks across rideshare sexual assault, toxic foam contamination, and blockbuster pharma dockets.
Mass Tort
Back-to-back North Carolina bench trials will establish binding damages formulas — stripping the Justice Department of its leverage to push lower administrative payouts.
BackgroundThe Camp Lejeune Justice Act allows veterans and military families exposed to contaminated drinking water between 1953 and 1987 to sue the federal government for damages. Hundreds of thousands of claims allege industrial solvents like benzene, vinyl chloride, and PCE caused terminal illnesses.
- U.S. District Judge Terrence Boyle scheduled the landmark Mousser kidney cancer trial for late October, followed immediately by the Fancher trial on November 9.
- The 4-judge federal panel extended the Plaintiffs' Leadership Group through late 2027 while ordering weekly settlement master sessions toward a comprehensive resolution framework.
- The Department of Justice Civil Division reported that elective administrative settlement offers have exceeded $1.1 billion across roughly 407,000 filed claims.
Mass Tort
Uber bought confidential peace hours before trial — keeping its background check records away from juries while thousands more passenger claims stack up.
BackgroundThousands of passengers sued Uber alleging the rideshare company failed to conduct adequate driver background checks and bypassed biometric safety monitoring to protect growth. Federal lawsuits are consolidated into multidistrict litigation before Judge Charles Breyer in San Francisco.
- Uber reached the confidential resolution in Jane Doe QLF 001 after jury selection concluded in Texas, avoiding scrutiny of internal screening logs.
- The settlement follows mixed prior bellwether results, including an $8.5 million jury verdict in Phoenix holding Uber responsible for driver misconduct under apparent agency doctrines.
- With approximately 4,916 individual claims pending in MDL No. 3084, plaintiffs' leadership is preparing the next tranche of federal bellwether trials for early 2027.
Mass Tort
Approaching deadlines for the $234M firefighting foam deal lock in municipal utility payouts — freeing the court to confront thousands of individual cancer claims.
BackgroundAqueous film-forming foam (AFFF) containing toxic per- and polyfluoroalkyl substances (PFAS) was used for decades at military airfields and municipal fire training facilities. Over 15,000 lawsuits allege PFAS chemicals contaminated drinking water aquifers, causing kidney cancer and thyroid disease.
- Settling defendants Carrier Global, Amerex Corp, Archroma U.S., and Nation Ford Chemical established a $234 million fund ahead of a January 2027 fairness hearing.
- Water districts have until November 23 to file objections and December 22 to opt out to pursue independent filtration claims.
- The settlements follow prior multi-billion-dollar deals with 3M and DuPont, while Judge Richard Gergel pivots the docket toward unliquidated personal cancer claims.
Mass Tort
Plaintiffs are leveraging European label warnings against Novo Nordisk and Eli Lilly — turning transatlantic packaging discrepancies into evidence of concealed stomach paralysis risks.
BackgroundBlockbuster GLP-1 receptor agonists Ozempic, Wegovy, and Mounjaro are widely prescribed for type 2 diabetes management and clinical weight loss. Patients allege drug manufacturers masked risks of gastroparesis, bowel obstruction, and non-arteritic anterior ischemic optic neuropathy (NAION).
- The gastroparesis MDL before Judge Karen Spencer Marston expanded to 4,025 pending actions, while a companion docket focusing on permanent NAION blindness reached 247 cases.
- Plaintiffs' discovery is scrutinizing differences between European warning labels that included earlier warnings and US package inserts that omitted explicit gastrointestinal risks.
- Manufacturers Novo Nordisk and Eli Lilly maintain that delayed gastric emptying is a known pharmacological mechanism that was appropriately disclosed on FDA-approved packaging.
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
